National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 35 years. - Assessment of Safety and Immunogenicity of Intravenous Immunization With Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) in Healthy African Adults.
University of Oxford - Recruiting 18 years to 45 years. - A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria.
Centers for Disease Control and Prevention - Recruiting 1 year or older. - Ethiopia Antimalarial in Vivo Efficacy Study 2012: Evaluating the Efficacy of Artemether-lumefantrine Alone Compared to Artemether-lumefantrine Plus Primaquine and Chloroquine Alone Compared to Chloroquine Plus Primaquine for Plasmodium Vivax Infection.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 45 years. - VRC 314: A Phase 1, Open-Label, Clinical Trial With Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Durability of Protection Following Intravenous and Intramuscular Administration of PFSPZ Vaccine in Malaria-Naive Adults.
National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 10 years. - Effect of Oral Activated Charcoal on Parasite Clearance Rates in Response to Intravenous Artesunate in Malian Children With Uncomplicated Plasmodium Falciparum Malaria.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 45 years. - Double Blind Dose-Escalating Randomized Controlled Phase 1 Study in Malaria Exposed Adults of the Safety and Immunogenicity of Pfs25-EPA/ Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum in Bancoumana, Mali.
Pfs25-EPA; Euvax/Hepatitis B vaccine; Menatra/Meningococcal Groups A, C, Y, W-135 vaccine; Alhydrogel
Ottawa Hospital Research Institute - Recruiting 18 years or older. - Incorporation of the 'Ottawa Malaria Decision Aid' Into the Pre-travel Consultation Process: Assessment of Travelers' Knowledge, Decisional Conflict, Preparation for Decision-making and Medication Adherence Compared to Standard Care.
Novartis - Recruiting 20 years to 60 years. - An Open Label, Single Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum Malaria Mono-infection.
Epicentre - Recruiting 6 Months to 59 Months. - Efficacy of Artesunate-amodiaquine, Dihydroartemisinin-piperaquine and Artemether-lumefantrine Combination Therapies for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Aged 6 to 59 Months in Maradi, Niger 2012-13.
Novartis - Recruiting 20 years to 60 years. - A Proof-of-concept, Open Label Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection.
Novartis - Recruiting N/A or older. - An Open-label, Single-arm Study to Evaluate the Efficacy, Safety and PK of Artemether-lumefantrine Dispersible Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants <5 kg Body Weight.
Institut National de la Sant Et de la Recherche Mdicale, France - Recruiting 20 years to 45 years. - Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel r as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults:a Staggered Phase Ia/Ib, Randomised, Double-blind, Multi-Centre Trial.
Group A1 : 50æg AMA1-DiCo + Alhydrogel; Group A2 : 50 æg AMA1-DiCo+ GLA-SE; Group B2 : Placebo
sigma-tau i.f.r. S.p.A. - Recruiting 6 Months to 12 Months. - A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamics and Safety Study of a New Paediatric Eurartesim Dispersible Formulation and Crushed Film Coated Eurartesim Tablet, in Infant Patients With P. Falciparum Malaria.
Eurartesim dispersible oral tablet; eurartesim film coated tablet
University of Oxford - Recruiting 6 years or older. - An Open-label Randomized Controlled Trial to Evaluate the Effectiveness and Safety of a 3 Day Versus 5 Day Course of Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria in Myanmar.
Artemether-lumefantrine 3 days; Artemether-lumefantrine 5 days
University of North Carolina, Chapel Hill - Recruiting 18 years to 70 years. - Impact of Host Iron Status and Iron Supplement Use on Growth and Viability of the Erythrocytic Stage of Plasmodium Falciparum.
Medicines for Malaria Venture - Recruiting 18 years to 60 years. - The Extended Observation Over a Period of 28 Days of the Effects of Single Doses of OZ439 on the Recrudescence of Plasmodium Falciparum Malaria - a PhIIa, Open Label Study in Adult Patients.
African Malaria Network Trust - Recruiting 12 Months to 48 Months. - Phase IIb Immunogenicity, Efficacy and Safety Study of P. Falciparum Vaccine Candidate, MSP3-LSP Adjuvanted in Aluminium Hydroxide Versus Verorab Control in Healthy Children Aged 12-48 Months in Mali..
MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP; Verorab vaccine